Evidence map›Paper›PMID 31581174›Full record

ArticleNature2019

Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.

Eunyoung Park, Shaun Rawson, Kunhua Li, Byeong-Won Kim, Scott B Ficarro, Gonzalo Gonzalez-Del Pino, Humayun Sharif, Jarrod A Marto, Hyesung Jeon, Michael J Eck

Open access · greenAbstract read
In one paragraph

Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers.

0numbers the graph read from it
0cells of the map it votes in
189citing papers in PubMed
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

189 citing papers in PubMed, 323 citations in OpenAlex.

  1. Article
  2. A complex of MAST1 and 14-3-3η regulates Tau phosphorylation in the developing cortex.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. MEK inhibitors loosen RAF's grip.Nature chemical biology · 2026
    Article
  12. Article
  13. Free Energy and Flexibility Analysis of Autoinhibited Human BRAF.Journal of chemical information and modeling · 2026
    Article
  14. Article
  15. Restoring the 14-3-3/CRAF regulatory interaction in Noonan syndrome using molecular glues.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

129 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Eunyoung ParkDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shaun RawsonDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Kunhua LiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Byeong-Won KimDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Scott B FicarroDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gonzalo Gonzalez-Del PinoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Humayun SharifDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jarrod A MartoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hyesung JeonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. hjeon@crystal.harvard.edu.
Michael J EckDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. eck@crystal.harvard.edu.
Dana-Farber Cancer Institute · USHarvard University · USBrigham and Women's Hospital · US

Funding

User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI MALCOLM S. CAPEL · 2018 to 2026
$34.2M
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Benjamin Harris Kann · 2013 to 2026
$33.5M
StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2012 to 2021
$17.8M
Structure, mechanism, and pharmacology of BRAF and its partners in the RAS/RAF/MAP kinase pathwayR35CA242461 · NCI · DANA-FARBER CANCER INST · PI ECK, MICHAEL J · 2019 to 2025
$7.4M
Structural biology and drug discovery targeting oncogenic EGFR and BRAF kinasesR50CA221830 · NCI · DANA-FARBER CANCER INST · PI PARK, EUNYOUNG · 2017 to 2021
$942k
NCI NIH HHS P01 CA154303NCI NIH HHS P50 CA165962NCI NIH HHS R35 CA242461NCI NIH HHS R50 CA221830NIGMS NIH HHS P30 GM124165NIH HHS GM124165
6 · The paper itself

Abstract

RAF family kinases are RAS-activated switches that initiate signalling through the MAP kinase cascade to control cellular proliferation, differentiation and survival

Indexed as

Cryoelectron Microscopy14-3-3 ProteinsBinding SitesCell Transformation, NeoplasticHumansMAP Kinase Kinase 1Models, MolecularMutationPhosphorylationProtein BindingProtein DomainsProtein MultimerizationProto-Oncogene Proteins B-raf14-3-3 ProteinsBRAF protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1Proto-Oncogene Proteins B-raf

Identifiers

PMID31581174
PMCPMC7014971
OpenAlexW2978479061

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.